results in 3184 patients of the AIEOP-BFM ALL 2000

Molecular response to treatment redefines all prognostic
factors in children and adolescents with B-cell precursor
acute lymphoblastic leukemia: results in 3184 patients of
the AIEOP-BFM ALL 2000 study
by Valentino Conter, Claus R. Bartram, Maria Grazia Valsecchi, André Schrauder,
Renate Panzer-Grümayer, Anja Möricke, Maurizio Aricò, Martin Zimmermann, Georg
Mann, Giulio De Rossi, Martin Stanulla, Franco Locatelli, Giuseppe Basso, Felix
Niggli, Elena Barisone, Günter Henze, Wolf-Dieter Ludwig, Oskar A. Haas, Giovanni
Cazzaniga, Rolf Koehler, Daniela Silvestri, Jutta Bradtke, Rosanna Parasole, Rita
Beier, Jacques J. M. van Dongen, Andrea Biondi, and Martin Schrappe
Blood
Volume 115(16):3206-3214
April 22, 2010
©2010 by American Society of Hematology
Event-free survival (A) and cumulative incidence of relapse (B) according to PCR-MRD
classification in 3184 pB-ALL patients.
Valentino Conter et al. Blood 2010;115:3206-3214
©2010 by American Society of Hematology
Prognostic impact of PCR-MRD in 762 TEL/AML1-positive patients (A), in 487 patients with
favorable DNA index (≥ 1.16 and < 1.6; B), and in 54 Ph+ patients (C).
Valentino Conter et al. Blood 2010;115:3206-3214
©2010 by American Society of Hematology
Prognostic impact of PCR-MRD in 3184 pB-ALL patients (Ph−) within subgroups according to
ALL-BFM 95 criteria: standard (1263 patients; A), medium (1684 patients; B), and high (237
patients; C).
Valentino Conter et al. Blood 2010;115:3206-3214
©2010 by American Society of Hematology
Prognostic value of TP1 and TP2 in 1777 non–MRD-HR patients (ie, patients with MRD < 10−3 at
TP2) who are MRD positive at TP1.
Valentino Conter et al. Blood 2010;115:3206-3214
©2010 by American Society of Hematology